Clinical trials: COVID-19, SARS-CoV-2
SARS-CoV2 Infection
Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines
The purpose of this study is to evaluate the efficacy, safety and immunogenicity of GX-19N in healthy individuals who have received one of COVID-19 vaccine authorized for emergency use.
- Trial name
- NCT05067946
- Testing
- GX-19N
- Volunteers
- healthy volunteers welcome
- Sponsor
- Genexine, Inc.
Long COVID
Amygdala Insula Retraining in the Management of Long COVID Symptoms
The goal of the study is to compare a mind body intervention against usual care in patients with fatigue with long COVID. Our research questions include 1. Is the mind body intervention additive to usual care in long COVID 2.
- Trial name
- NCT05851846
- Testing
- Amygdala insula retraining
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- Miami VA Healthcare System
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)
This is a Phase IIb, randomized, controlled, observer-blinded, clinical trial to evaluate safety and immunogenicity of COVID-19 Vaccine HIPRA in adult healthy volunteers in Vietnam
- Trial name
- NCT05142514
- Testing
- COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech)
- Where
- Vietnam
- Volunteers
- 629 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
COVID, SARS-CoV 2
COVID19 Clinical Predictors and Outcome
In December 2019, a novel coronavirus (SARS-CoV-2) emerged in Wuhan, Hubei, China, and now spreads across international borders.
- Trial name
- NCT04416347
- Testing
- SARS-CoV2 Infection
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- St George's University Hospitals NHS Foundation Trust
Sars-CoV-2 Infection
Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment
The Coronavirus Disease 2019 (COVID-19) pandemic has claimed over 5 million lives globally. Fortunately, a substantial and growing number of SARS-CoV-2 vaccines with very high efficacy have been developed, manufactured, and…
- Trial name
- NCT05119738
- Testing
- Three doses of BNT162b2 (observational), Two doses of Coronavac and one dose BNT162b2 (observational)
- Where
- Chile
- Volunteers
- 122 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Covid19
Seroprevalence of SARS-CoV-2 in Asymptomatic Frontline COVID-19 HCWs
This study is about the current knowledge on the immunological changes observed in various healthcare workers in this part of the world, who remained asymptomatic while working in high exposure areas of COVID-19 infection.
- Trial name
- NCT04563247
- Testing
- IgG SARS CoV 2 antibodies
- Where
- Pakistan
- Volunteers
- 970 people
- Sponsor
- Lahore General Hospital
COVID-19, Sars-CoV-2 Infection
Booster Vaccination Against COVID-19
A booster dose of vaccine (Turkovac or CoronaVac) will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
- Trial name
- NCT04979949
- Testing
- CoronaVac, Turkovac
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
Covid19
COVID 19 Preventive Measures Among Mansoura Nursing Students
This study aims to identify nursing students knowledge gaps, risk perceptions and adherence to COVID 19 preventive measures during written exam period and In addition due to the possibility of being infected with COVID-19 during…
- Trial name
- NCT04473547
- Where
- Egypt
- Volunteers
- 144 people
- Sponsor
- Mansoura University
Psychological
Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period : Prospective Cohort.
The outbreak linked to SARS-CoV-2 infection was declared a Public Health Emergency of International Concern on 30 January 2020. In all of the emergency Departments, a major reorganization was necessary, notably with the creation…
- Trial name
- Resi-CoV (NCT04349163)
- Testing
- Questionnaire
- Where
- France
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
COVID19
Part 2 on the Study Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children (COVILLE2) (WHO)
France and in particular the paris area was one of the countries most affected by the pandemic Covid19. School closures and a generalized lockdown of the population were instituted in France from 17 March 2020 to 10 May 2020.
- Trial name
- COVILLE2 (NCT04416893)
- Testing
- RT-PCR SARS-Cov2, Sars-Cov2 serology
- Volunteers
- healthy volunteers welcome
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Covid19
Serological Profile of Children and Young Adolescents With at Least One COVID-19 Diagnosed Family Member
Use of rapid serological tests to assess the vulnerability to SARS-CoV-2 infection of subjects aged 4-16 years old and cohabiting with at least one family member who tested positive to SARS-CoV-2
- Trial name
- NCT04649944
- Testing
- Serological test and phone interview
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Milan
Covid19
Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).
Hypothesis: The apelin/APJ system is involved in the protection of the lung affected by the COVID-19 by interacting with the SARS-coV-2 entry door: the Angiotensin I Converting Enzyme 2 (ACE2) and the renin-angiotensin system…
- Trial name
- APEL-COVID (NCT04632732)
- Testing
- COVID-19 test, Blood sampling
- Where
- Canada
- Volunteers
- 140 people
- Sponsor
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
SARS-CoV-2
A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults
To evaluate immune responses of an Investigational mRNA-1273.815 vaccine against the Omicron subvariant strain (XBB.1.5) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT06354998
- Testing
- Investigational mRNA-1273.815, Licensed Spikevax Vaccine
- Where
- 7 sites in Australia
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
Phase Ⅱ and Ⅲ Trial of a SARS-CoV-2 Vaccine LYB001
The phase Ⅱ trial adopts a randomized, double-blind, placebo-controlled design to evaluate the immunogenicity and safety profile of LYB001 in healthy adults aged 18 years and older.
- Trial name
- NCT05137444
- Testing
- LYB001
- Volunteers
- 1,900 people, healthy volunteers welcome
- Sponsor
- Yantai Patronus Biotech Co., Ltd.
COVID-19
PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of PF-07304814 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780541
- Testing
- PF-07304814, Remdesivir
- Where
- 40 sites in United States, Denmark
- Volunteers
- 58 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)
COVID-19 is a respiratory disease caused by the new coronavirus (SARS-CoV-2) and causes considerable morbidity and mortality. Currently, there is no vaccine or therapeutic agent to prevent and treat a SARS-CoV-2 infection.
- Trial name
- TOCOVID (NCT04332094)
- Testing
- Tocilizumab, Hydroxychloroquine, Azithromycin
- Where
- 7 sites in Spain
- Volunteers
- 276 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
SARS-CoV-2 Infection
Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction [RT-PCR] test)…
- Trial name
- SCORPIO-PEP (NCT05897541)
- Testing
- S-217622
- Where
- 178 sites in United States, Argentina and 3 more
- Volunteers
- 3,701 people, healthy volunteers welcome
- Sponsor
- Shionogi
SARS-CoV-2, Covid19
National Survey Concerning Vaccination Against COVID-19 in Nursing Homes and Long-Term Care Units
The COVID-19 pandemic is a challenge for the French healthcare system, particularly among the elderly due to their particular vulnerability to the serious consequences of the disease, with an estimated mortality rate of around…
- Trial name
- VACOVID-SENIOR (NCT04779541)
- Testing
- observation
- Where
- France
- Volunteers
- 323 people
- Sponsor
- University Hospital, Angers
Long COVID Syndrome
Characteristics of Long COVID-19 Syndrome
Characterization of patients with long COVID syndrome including symptoms, medical history and persistent organ damage.
- Trial name
- NCT04793269
- Testing
- No intervention
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- Christian Clarenbach
Covid19
Study of Socio-demographic Factors, Behaviors and Practices Associated With Infection With SARS-CoV-2 Responsible for COVID-19
The objective of the study is to identify socio-demographic factors, behaviors and practices associated with infection with SARS-CoV-2 to help determine where and how patients mostly get infected with SARS-CoV-2.
- Trial name
- ComCor (NCT04607941)
- Testing
- Questionnaires, Phone interviews
- Where
- 2 sites in France
- Volunteers
- 766,818 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.